Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Either one of the following risk factors is sufficient for inclusion (high risk patient)

• Previous cerebral ischaemic attack (stroke or transient ischaemic attack (TIA), >30 days prior to randomization)

• Previous systemic embolism or at least one of the following risk factors are needed for inclusion: Age ≥75 years

• Symptomatic congestive heart failure

• Impaired left ventricular systolic function

• Diabetes mellitus; Hypertension requiring anti-hypertensive treatment

• In addition to AF the patient must be appropriate for but unable or unwilling to take VKA therapy

Exclusion Criteria:

• Presence of a clinically significant valvular heart disease;; Stroke or TIA and/or systemic embolism within the previous 30 days prior to randomization

• Conditions associated with increased risk of major bleeding